Compare · IBO vs LLY
IBO vs LLY
Side-by-side comparison of Impact BioMedical Inc. (IBO) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBO and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.36T, about 30578.2x IBO ($44.4M).
- Over the past year, IBO is down 41.8% and LLY is up 41.0% - LLY leads by 82.8 points.
- LLY has been more active in the news (38 items in the past 4 weeks vs 14 for IBO).
- LLY has more recent analyst coverage (25 ratings vs 0 for IBO).
- Company
- Impact BioMedical Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $44.4M
- $1.36T
- 1M return
- -2.84%
- +15.42%
- 1Y return
- -41.84%
- +40.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 14
- 38
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest IBO
- SEC Form 10-Q filed by Impact BioMedical Inc.
- Chief Operating Officer Suseck Mark gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Zimmerman Christian Thomas gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Hibbert Castel Berisford gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Sims Melissa Kaye gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Keene David K gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Brownell Elise gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Chan Heng Fai Ambrose gave a grant of 4,170 shares, decreasing direct ownership by 11% to 32,112 units (SEC Form 4)
- Director Grady Jason gave a grant of 4,170 shares, decreasing direct ownership by 13% to 28,164 units (SEC Form 4)
- Chief Financial Officer Macko Todd D gave a grant of 4,170 shares, decreasing direct ownership by 20% to 16,462 units (SEC Form 4)
Latest LLY
- Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
- Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines